To date, multiple immune checkpoint inhibitors (blocking either CTLA-4, PD-1, or PD-L1) are approved for more than 15 different cancer entities, however, efficacy has so far been most promising in solid tumors (Table 1). Here, CTLA4 is linked to cancer.